A pivotal trial for a next-generation blood thinner developed by Bristol Myers Squibb and Johnson & Johnson has concluded unsuccessfully. The drug, known as...
Johnson & Johnson’s newly-approved immunology treatment, Imaavy, has encountered a significant setback in its Phase 2a trial for treating rheumatoid arthritis. The trial results,...